Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | mitogen-activated protein kinase 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | mitogen-activated protein kinase 5 | mitogen-activated protein kinase 1 | 360 aa | 361 aa | 33.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | serine/threonine protein kinase | 0.0971 | 1 | 1 |
Plasmodium falciparum | protein serine/threonine kinase-1 | 0.0068 | 0.005 | 0.5 |
Giardia lamblia | Kinase, CMGC CLK | 0.0068 | 0.005 | 1 |
Echinococcus granulosus | mitogen activated protein kinase | 0.0065 | 0.0022 | 0.0022 |
Trypanosoma cruzi | kinetoplastid kinetochore protein 10, putative | 0.0068 | 0.005 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0068 | 0.005 | 0.0028 |
Trypanosoma brucei | kinetoplastid kinetochore protein 19 | 0.0068 | 0.005 | 1 |
Echinococcus granulosus | dual specificity protein kinase clk2 | 0.0068 | 0.005 | 0.005 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0068 | 0.005 | 0.0028 |
Toxoplasma gondii | cell-cycle-associated protein kinase CLK, putative | 0.0068 | 0.005 | 1 |
Leishmania major | protein kinase, putative | 0.0068 | 0.005 | 1 |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.0065 | 0.0022 | 0.0022 |
Trypanosoma cruzi | kinetoplastid kinetochore protein 19, putative | 0.0068 | 0.005 | 1 |
Echinococcus multilocularis | mitogen activated protein kinase 3 | 0.0065 | 0.0022 | 0.0022 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0068 | 0.005 | 1 |
Leishmania major | protein kinase, putative | 0.0068 | 0.005 | 1 |
Echinococcus multilocularis | MAP kinase activated protein kinase 2 | 0.0971 | 1 | 1 |
Trypanosoma cruzi | kinetoplastid kinetochore protein 19, putative | 0.0068 | 0.005 | 1 |
Loa Loa (eye worm) | CMGC/CLK protein kinase | 0.0068 | 0.005 | 0.005 |
Brugia malayi | Protein kinase domain containing protein | 0.0068 | 0.005 | 0.0028 |
Echinococcus granulosus | MAP kinase activated protein kinase 2 | 0.0971 | 1 | 1 |
Trypanosoma brucei | kinetoplastid kinetochore protein 10 | 0.0068 | 0.005 | 1 |
Trypanosoma cruzi | kinetoplastid kinetochore protein 10, putative | 0.0068 | 0.005 | 1 |
Loa Loa (eye worm) | camk/mapkapk/mapkapk protein kinase | 0.0971 | 1 | 1 |
Plasmodium vivax | serine/threonine kinase-1, putative | 0.0068 | 0.005 | 0.5 |
Echinococcus multilocularis | dual specificity protein kinase clk2 | 0.0068 | 0.005 | 0.005 |
Echinococcus multilocularis | mitogen activated protein kinase | 0.0065 | 0.0022 | 0.0022 |
Echinococcus granulosus | mitogen activated protein kinase 3 | 0.0065 | 0.0022 | 0.0022 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.3037 nM | BindingDB_Patents: IMAP-FP Assay. Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was determined from a 10 point (1:3 serial dilution, 3 uM starting compound concentration) titration curve using the following outlined procedure. To each well of a black Corning 384-well plate (Corning Catalog #3575), 7.5 mL of compound (3333 fold dilution in final assay volume of 25 uL) was dispensed, followed by the addition of 15 uL of kinase buffer (tween containing kinase buffer, Molecular Devices) containing 0.0364 ng/mL (0.833 nM) of phosphorylated active hERK2 enzyme. Following a 15 minute compound & enzyme incubation, each reaction was initiated by the addition of 10 uL kinase buffer containing 2.45 uM ERK2 IMAP substrate peptides (2.25 uM-unlabeled IPTTPITTTYFFFK-COOH and 200 nM-labeled IPTTPITTTYFFFK-5FAM (5-carboxyfluorescein)-COOH), and 75 uM ATP. | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.